Investment Bridge, one of Japan's leading IR services companies, has released a
“Bridge Report” on euglena Co., Ltd. (TOKYO Mothers: 2931) reviewing first
half fiscal year September 2013 earnings results and full year fiscal year
September 2013 earnings estimates.
* euglena Co., Ltd. is the world's first biotechnology company to succeed in
outdoor mass culture of edible Euglena microalgae.
* Sales of food products in the direct sales business exceeded food sales of the
health care business, which is trending favorably, due to fortification of the
marketing structure and increases in brand awareness of the main product of
“euglena farm Vegetable Juice (Japanese: “Midorijiru”).”
* Steady progress is being made in the achievement of three initial objectives
of the research and development for bio-jet fuels.
* Key points of euglena's strategy include the speed of expansion of its direct
sales business over the near term and commercialization of the jet fuel business
by 2018 over the medium term.
euglena is the world's first biotechnology company to succeed in outdoor mass
culture of edible euglena microalgae. Euglena has superior characteristics that
can be leveraged in foods, cosmetics, chemical products, feeds, fuels and other
products. Amongst the strengths of euglena Co., Ltd. are the high profitability
and stable cash flow of its health care business, and strong research and
development function, which collaborates with famous corporations and
About Bridge Report:
Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate
and objective information about the earnings, business strategies, and other
information of publicly traded Japanese companies.
Investment Bridge Co., Ltd.
Contributed via: Bloomberg Publisher WEB Service
Press spacebar to pause and continue. Press esc to stop.